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 Abstract. The spread of coronavirus disease (COVID-19/SARS-CoV-2) in 
Nigeria from index to community cases is becoming alarming that what the 
future holds should be brought to bear. An analytical study and time 
prediction model have been conducted on the epidemiological spread of 
coronavirus (COVID-19/SARS-CoV-2) with data collected from records of 
selected epicentres in Nigeria. The data was collected between March 1 
and May 31, 2020. It can be shown that the highest daily infection in March 
was recorded on the 28th with 32 infections while the highest fatality rate 
was recorded on 24th with a rate of 2.3% and recorded daily infection of 10. 
As at the 31st, a total number of 139 confirmed cases were recorded in 
Nigeria with a fatality and discharge rates of 1.4 and 6.5% respectively. It 
can be deduced that the highest daily infection in Nigeria in April was 
recorded on 30th, with daily infection of 204 confirmed cases. The highest 
discharge rate of 34.4% was recorded on 16th, with a fatality rate of 2.9% 
while the highest fatality rate of April was 3.5% recorded on 18th, which has 
a discharge rate of 30.6% and a daily infection record of 49. As of April 30, 
2020, Nigeria had recorded a total of 1932 confirmed cases with 58 deaths. 
It can also be deduced that the highest daily infection in Nigeria in May was 
recorded on 30th, with daily infection of 553 confirmed cases. It can also 
be observed that the highest discharge and fatality rates for May 2020 are 
29.6% and 3.6% recorded on 31st and 2nd respectively. As of May 31, 2020, 
the total infection stood at 10162 confirmed cases and there seems to be a 
continuing upward trajectory for the situation under investigation. It can 
also be observed that the rate of discharged cases continued to surpass 
those of the fatality for the months of investigation. No doubts that the 
COVID-19/SARS-CoV-2 was first recorded in the Ogun State of Nigeria, but 
Lagos state has surpassed both the daily infections and the cumulative 
infections for the country. With collected data, MLR simple linear regression 
extension was used to estimate an outcome or target variable based on two 
or more independent variables. The variables which are the three months 
data collected from daily infections, totally confirmed case, total deaths 
and total discharged cases between March 1, 2020, and May 31, 2020, were 
used to propose regression equations for the prediction of the cases under 
study for anytime period. 
Keywords: Coronavirus; Time Prediction Model; Epidemiological Spread; 
Epicentre of Viral Infection; Confirmed Cases; Discharged Cases; 
Intravascular Coagulation; Biomedicine; Pneumonia; Symptomatic 
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INTRODUCTION 
Coronavirus disease is a potentially severe acute 
respiratory infection caused by severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2). 
According to WHO, 44 cases of pneumonia of un-
known microbial etiology entangled with Wuhan 
city, Hubei province china on 31 December 2019 
[12, 5]. According to [2] 87 % of confirmed cases 
were aged 30 to 79 years, 1 % were aged 80 
years or older. Approximately 51 % of patients 
were male and 49 % were female. In the US older 
patients aged greater than or equal to 65 years 
accounted for 31 % of all cases, 45 % of hospi-
talizations, 53 % of intensive care unit admis-
sions and 80 % of deaths, with the highest inci-
dence of severe outcomes in patients aged 
greater than or equal to 85 years [4]. According 
to findings, weather conditions may influence the 
transmission of COVID-19, with cold and dry 
conditions appearing to increase transmission, 
and warm and humid conditions reducing the 
risk of cases and deaths in some countries [11]. 
Most common symptoms of COVID-19 include 
fever, cough, dyspnea, myalgia, fatigue, altered 
sense of taste/smell, while less common symp-
toms include sore throat, confusion, dizziness, 
headache, rhinorrhea, or nasal congestion, 
hemoptysis, chest pain, conjunctivitis, cutaneous 
manifestations [14] (Figure 1).  
 
 
Figure 1 – COVID-19/SARS-CoV-2 origin, infectious and effect factors on humans [8] 
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Approximately 90 % of patients present with 
more than one symptom, and 15 % of patients 
present with fever, cough, and dyspnea. On Janu-
ary 7, a novel coronavirus was identified by the 
Chinese centre of Disease Control and Prevention 
(CDC) from the throat swab sample of a patient 
and was subsequently named 2019-nCoV by 
WHO [12, 5]. According to [8], COVID-19 can 
cause multiple system infections in respiratory 
tract infections in humans, such as Severe Acute 
Respiratory Syndrome (SARS) and Middle East 
Respiratory Syndrome (MERS). The following 
research was carried out in china on patients 
with SARS-CoV-2 according to age. 10 % of these 
patients were less than or equal to 39 years old, 
22 % of these patients were 40-49 years old, 
30 % – 50-59 years old, 22 % – 60-69 years old, 
15 % – greater than or equal to 70 years old. The 
same research was carried out according to sex. 
There were 32 % of female patients and 68 % of 
male patients. 
Epicentres/severely affected countries on the epi-
demiological spread of COVID-19/SARS-CoV-2 
across continents. According to [10] between late 
February and the early march of 2020, the indi-
vidual data of laboratory-confirmed cases of 
COVID-19 were retrieved from 10728 publicly 
available reports released by the health authori-
ties of and outside china and from 1790 publica-
tions identified in PubMed and CNKI. According 
to [13], Europe has become the new epicentre of 
the COVID-19 pandemic. Italy was initially the 
county hit the hardest by far Spain, the Nether-
lands and other followed. France and Germany 
had experienced the first importation of cases 
already in January. On 10 March, the total num-
ber of fatalities in Italy exceeded 3,000, topping 
the total number of reported fatalities in china. 
Outside Europe, Iran faced a rapid surge of 
COVID-19 followed by the exportation of cases 
mostly to countries in the Middle East [3]. The 
United States in North America and Europe in the 
United Kingdom emerged as new epicentre with 
124,655 cases plus 1,019 fatalities respectively, 
reported by 29 March [6]. Recently increasing 
case numbers have also been seen in Africa and 
Asian countries outside China [9]. 
The novel coronavirus has two modes of trans-
mission which includes droplets with a particle 
size of 5-10 µm and transmissible distance of ˂3 
ft. SARS-CoV-2 survives on surface materials like 
copper with a half-life of 1 hour and a total time 
of detectability of 8 hours, cardboard with a half-
life of 3 hours and a total time of detectability of 
48 hours, and plastic with a half-life of 7 hours 
and a total time of detectability of 72 hours. SARS 
(Severe Acute Respiratory Syndrome) started 
onset November 2002 [9]. Its last known case 
was 2004. MERS (Middle East Respiratory Syn-
drome) started onset 2012 in Saudi Arabia. Saudi 
Arabia outbreak in 2004 recorded 402 cases and 
27 % mortality. South Korea outbreak in 2015 
recorded 105 cases and 17% mortality. United 
States outbreak recorded 2 cases in 2014, includ-
ing health care workers travelling from Saudi 
Arabia [15].  
COVID-19 Timeline showed that from December 
31-January 3, 2020, 44 cases of pneumonia of 
unknown cause was reported in Wuhan [3, 13]. 
On January 7, 2020, new coronavirus was identi-
fied. On January 13, 2020: Thailand, on January 
15, 2020: Japan, on January 20, 2020: South Ko-
rea, on January 23, 2020: the United States and 
on April 4, 2020, worldwide cases surpassed 
1 million [10].  
The novel COVID-19 was declared a global pan-
demic by the World Health Organization (WHO) 
on the 11 March 2020. The WHO has reported an 
incubation period for COVID-19 between 2 and 
10 days. However, according to research incuba-
tion period can last for longer than two weeks. 
However, according to [3, 1], cases reported in 
china according to location and patients in-
clude; Mainland china – 364 (72 %), Beijing – 
133 (26 %), Shaanxi – 87 (17 %), Hubei – 41 
(8 %), Tianjin – 22 (4 %), Yunnan – 19 (4 %). 
And the mortality rate around the world vary by 
country as of the first week of April 2020 as fol-
lows; China – 4.0 %, South Korea – 1.8 %, Italy – 
12.5 %, Spain – 9.7 %, Iran – 6.2 %, United States 
– 3.2 %, worldwide – 5.6 %. As of April 7th 2020, 
1,353,361 confirmed cases worldwide, 79,235 
confirmed deaths, 212 counties, areas or territo-
ries with cases. 
Epicentres/severely affected states on the epide-
miological spread of COVID-19/SARS-CoV-2 Nige-
ria. The report has shown that coronavirus is one 
of the major pathogens that mainly targets the 
human respiratory system [7]. The first case of 
COVID-19 was reported in December 2019. From 
December 18, 2019, through December 29, 2019, 
five patients were hospitalized with acute respi-
ratory distress syndrome. By January 2, 2020, 
41 admitted hospital patients had been identified 
as having laboratory-confirmed COVID-19 infec-
tions, less than half of the patients had underly-
ing diseases including diabetes, hypertension, 
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and cardiovascular diseases. Different bodies in-
cluding the WHO and the US Centres for Disease 
Control and Preventions (CDC) have issued ad-
vice on preventing further spread of COVID-19. 
They have advised that travel to high-risk areas 
should be avoided, and contact with sympto-
matic patients should also be avoided. Basic hand 
hygiene measures are also recommended includ-
ing frequent hand washing. The SARS-CoV-2 pos-
sesses a single strand, positive-sense RNA ge-
nome ranging from 26-32 kilobases in length. 
Coronavirus has been identified in various 
mammals including camels, bats, masked palm 
civets, mice, dogs and cats. The COVID-19/SARS-
CoV-2 was first recorded in the Ogun State of Ni-
geria, but Lagos state has surpassed both the 
daily infections and the cumulative infections for 
the country. On May 30, 2020, Lagos state re-
corded a daily total of 378 confirmed cases and 
Kano state has continued to follow in the rate at 
which cases are confirmed in Nigeria and fol-
lowed by the other 8 states. Also beyond these 10 
states in view, the tide is changing towards the 
south-south and south-east regions of Nigeria 
and this demands urgent study.  
 
METHODOLOGY 
Data Collection. The data for this work was col-
lected using sampling method and released in-
formation from the WHO, CDC and NCDC on daily 
monitoring of the recorded cases of events across 
the world and particularly Nigeria. The collation 
of the data took three months spanning between 
March 1 and May 31, 2020. The cumulative daily 
cases of infection, discharged and deaths were 
collated and the rates of discharge and deaths 
were computed by common calculation. A litera-
ture search was also incorporated and lastly, a 
graphical analysis of the epidemiological spread 
of the COVID-19/SARS-CoV-2 was conducted. 
Model Development and Statistical Hypothesis. 
MLR is a simple linear regression extension used 
to estimate an outcome or target variable based 
on two or more independent variables. The ex-
pected parameter to be estimated is termed the 
dependent or outcome variable, which is total 
case discharged, total deaths and total case con-
firmed within a study period. The variables or 
factors utilized to produce the estimation results 
are termed the predictor/independent/criterion 
variables or explanatory variables, which are the 
three months data collected from daily infections, 
totally confirmed case, total deaths and total dis-
charged cases between March 1, 2020, and May 
31, 2020. MLR aids in the determination of the 
variance explained (overall fit) of the model in 
terms of respective contributions of each ex-
planatory parameter to the total variance ex-
plained. It is also used to assess the relationship 
strength which exists between two or more vari-
ables and its respective target variables. 
The descriptive statistics of the data utilized for 
the model development which consist of epide-
miological statistics of COVID-19/SARS-CoV-2 
cases in Nigeria for three months duration are 
presented in Table 1. 
 
Table 1 – Statistical parameters of data sets for the model development 
Model Variables SE Mean SD Range SV Minimum Maximum 
Duration 2.78 46.50 26.70 91 713.00 1 92 
Daily infections 13.43 110.61 128.84 553 16601.03 0 553 
% discharge 1.12 16.26 10.71 34.4 114.80 0 34.4 
Total discharged 86.52 541.86 829.85 3007 688659.22 0 3007 
Total deaths 9.17 65.90 87.96 287 7737.47 0 287 
Total confirmed cases 309.33 2188.36 2966.98 10161 8802971.75 1 10162 
 
Statistical Hypothesis: 
Null Hypothesis: all the parameters of predictors 
are not significantly different from zeros which 
implies that the model is not statistically signifi-
cant. This is expressed mathematically in For-
mula 1:  
0...: 210  nH      (1) 
Alternate Hypothesis: at least one predictor pa-
rameter is significantly different from zero that is 
the model is statistically significant. This is ex-
pressed mathematically in Formula 2: 
0...: 211  nH      (2) 
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RESULTS AND DISCUSSION 
Epidemiological timeline of COVID-19/SARS-CoV-2 
spread in Nigeria from March 1, 2020 to May 31, 
2020. Tables 2–3 and Figures 2–7 represent the 
epidemiological timeline of COVID-19/SARS-
CoV-2 spread in Nigeria from March 1, 2020, to 
May 31, 2020, which show the epidemiological 
statistics of COVID-19/SARS-CoV-2 cases and 
discharge and death rates in Nigeria within the 
studied period.  
Table 2 – March 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in Nigeria 
Date Total confirmed cases Daily infections Total discharged % discharge Total deaths % deaths 
1 1 1 0 0 0 0 
2 1 0 0 0 0 0 
3 1 0 0 0 0 0 
4 1 0 0 0 0 0 
5 1 0 0 0 0 0 
6 1 0 0 0 0 0 
7 1 0 0 0 0 0 
8 1 0 0 0 0 0 
9 1 0 0 0 0 0 
10 2 1 0 0 0 0 
11 2 0 0 0 0 0 
12 2 0 0 0 0 0 
13 2 0 0 0 0 0 
14 2 0 0 0 0 0 
15 2 0 0 0 0 0 
16 3 1 1 33.3 0 0 
17 3 0 1 33.3 0 0 
18 8 5 1 12.5 0 0 
19 12 4 1 8.3 0 0 
20 12 0 1 8.3 0 0 
21 22 10 2 9.1 0 0 
22 24 2 2 8.3 0 0 
23 33 9 2 6.1 1 3 
24 44 10 2 4.5 1 2.3 
25 51 7 2 3.9 1 2 
26 65 14 3 4.6 1 1.5 
27 65 0 3 4.6 1 1.5 
28 97 32 3 3.1 1 1 
29 111 14 3 2.7 1 0.9 
30 131 20 8 6.1 2 1.5 
31 139 8 9 6.5 2 1.4 
 
Table 3 – April 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in Nigeria 
Date Total confirmed cases Daily infections Total discharged % discharge Total deaths % deaths 
1 174 35 9 5.2 2 1.1 
2 184 10 20 10.9 2 1.1 
3 210 26 25 11.9 4 1.9 
4 214 4 25 11.7 4 1.9 
5 232 18 33 14.2 5 1.5 
6 238 6 35 14.7 5 2.1 
7 254 16 44 17.3 6 2.4 
8 276 22 44 15.9 6 2.2 
9 288 12 51 17.7 7 2.4 
10 305 17 58 18.8 7 2.3 
11 318 13 70 22.0 10 3.1 
12 323 5 85 26.3 10 3.1 
13 343 20 91 26.5 10 2.9 
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Date Total confirmed cases Daily infections Total discharged % discharge Total deaths % deaths 
14 373 30 99 26.5 11 2.9 
15 407 34 128 31.4 12 2.9 
16 442 35 152 34.4 13 2.9 
17 493 51 159 32.3 17 3.4 
18 542 49 166 30.6 19 3.5 
19 627 85 170 27.1 21 3.3 
20 665 38 188 28.3 22 3.3 
21 782 117 197 25.2 25 3.2 
22 873 91 197 22.6 28 3.2 
23 981 108 197 20.1 31 3.2 
24 1097 116 208 19.0 32 2.9 
25 1182 85 222 18.8 35 3.0 
26 1273 91 239 18.8 40 3.1 
27 1337 64 255 19.1 40 3.0 
28 1532 195 255 16.6 44 2.9 
29 1728 196 307 17.8 51 3.0 
30 1932 204 319 16.5 58 3.0 
 
Table 4 – May 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in Nigeria 
Date Total confirmed cases Daily infections Total discharged % discharge Total deaths % deaths 
1 2170 238 351 16.2 68 3.1 
2 2388 218 358 15.0 85 3.6 
3 2558 170 400 15.6 87 3.4 
4 2802 244 417 14.9 93 3.3 
5 2950 148 481 16.3 98 3.3 
6 3147 197 534 17.0 103 3.3 
7 3526 379 601 17.0 107 3.0 
8 3912 386 679 17.4 117 3.0 
9 4151 239 745 17.9 128 3.1 
10 4399 248 778 17.7 143 3.3 
11 4641 242 902 19.4 150 3.2 
12 4787 146 959 20.0 158 3.3 
13 4971 184 1070 21.5 164 3.3 
14 5162 193 1180 22.9 167 3.2 
15 5445 288 1320 24.2 171 3.1 
16 5621 176 1472 26.2 176 3.1 
17 5959 338 1594 26.7 182 3.1 
18 6175 216 1644 26.6 191 3.1 
19 6401 226 1734 27.1 192 3.0 
20 6677 284 1840 27.6 200 3.0 
21 7016 339 1907 27.2 211 3.0 
22 7261 245 2007 27.6 221 3.0 
23 7526 265 2174 28.9 221 2.9 
24 7839 313 2263 28.9 226 2.8 
25 8068 229 2311 28.6 233 2.9 
26 8344 276 2385 28.6 249 3.0 
27 8733 389 2501 28.6 254 2.9 
28 8915 182 2592 29.1 259 2.9 
29 9302 387 2697 29.0 261 2.8 
30 9855 553 2856 29.0 273 2.4 
31 10162 307 3007 29.6 287 2.8 
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Figure 2 – March 2020 epidemiological timeline of COVID-19/SARS-CoV-2 spread in Nigeria 
 
 
Figure 3 – March 2020 epidemiological timeline of COVID-19/SARS-CoV-2 discharge and deaths rates in Nigeria 
 
 
Figure 4 – April 2020 epidemiological timeline of COVID-19/SARS-CoV-2 spread in Nigeria 
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Figure 5 – April 2020 epidemiological timeline of COVID-19/SARS-CoV-2 discharge and death rates in Nigeria 
 
 
Figure 6 – May 2020 epidemiological timeline of COVID-19/SARS-CoV-2 spread in Nigeria 
 
 
Figure 7 – May 2020 epidemiological timeline of COVID-19/SARS-CoV-2 discharge and deaths rates in Nigeria 
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It can be shown from Table 2 and Figures 2–3 
that the highest daily infection was recorded on 
the 28th of March with 32 infections while the 
highest fatality rate was recorded on March 24th 
with a rate of 2.3 % and recorded daily infection 
of 10. As of March 31, 2020, a total number of 
139 confirmed cases were recorded in Nigeria 
with a fatality and discharge rates of 1.4 and 
6.5 % respectively.  
Table 3 and Figures 4–5 present the studied 
cases for April 2020. It can be deduced that the 
highest daily infection in Nigeria in April was re-
corded on April 30, 2020, with daily infection of 
204 confirmed cases. The highest discharge rate 
of 34.4 % was recorded on April 16, with a fatal-
ity rate of 2.9% while the highest fatality rate of 
April was 3.5 % recorded on April 18, 2020, 
which has a discharge rate of 30.6 % and a daily 
infection record of 49. As of April 30, 2020, Nige-
ria had recorded a total of 1932 confirmed cases 
with 58 deaths.  
Table 4 and Figures 6–7 present the studied 
cases for May 2020. It can be deduced that the 
highest daily infection in Nigeria in May was re-
corded on May 30, 2020, with daily infection of 
553 confirmed cases. It can also be observed that 
the highest discharge and fatality rates for May 
2020 are 29.6% and 3.6% recorded on May 31, 
2020, and May 2, 2020, respectively. As of May 
31, 2020, the total infection stood at 10162 con-
firmed cases and there seems to be a continuing 
upward trajectory for the situation under inves-
tigation. From Figures 3, 5, 7, it can be observed 
that the rate of discharged cases continued to 
surpass those of the fatality for the months of in-
vestigation. 
Epicentres/severely affected states of the epidemi-
ological spread of COVID-19/SARS-CoV-2 in Nige-
ria in May 2020. Table 5 and Figures 8–9 repre-
sent the epidemiological timeline of COVID-
19/SARS-CoV-2 spread in the most affected 
states (epicentres) in Nigeria for May 2020, 
which show the epidemiological statistics of 
COVID-19/SARS-CoV-2 daily infections within 
the studied period.  
 
Table 5 – May 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in 10 most severely affected 
states in Nigeria 
Date Lagos Kano FCT Katsina Bauchi Borno Ogun Oyo Jigawa Kaduna 
1 30 52 36 - 10 3 - 6 - - 
2 62 7 52 - 5 6 - 4 - 31 
3 39 29 12 8 18 7 24 1 - 15 
4 76 23 19 37 9 18 5 5 32 - 
5 43 32 10 9 3 6 6 5 - 3 
6 82 30 9 3 - 10 4 8 - 1 
7 183 55 - 11 19 9 5 3 44 7 
8 176 63 20 31 15 17 13 4 - 3 
9 97 29 7 19 44 17 2 5 - 3 
10 81 26 13 - 20 26 2 - 35 - 
11 88 64 3 49 1 1 9 1 - 13 
12 57 27 1 3 8 2 1 4 - - 
13 51 14 10 16 16 - - 4 23 5 
14 58 46 9 - 1 3 7 - 35 - 
15 179 8 7 15 3 13 11 13 15 20 
16 95 - 11 - 2 8 - 12 6 - 
17 177 64 21 9 3 3 - 11 4 4 
18 74 17 4 33 7 8 8 19 - 3 
19 131 - 5 - 2 4 25 6 4 7 
20 199 5 8 - - 8 - 19 6 - 
21 139 28 11 22 4 - 5 28 14 18 
22 132 8 1 5 - 12 13 9 16 9 
23 133 - 22 - 2 3 23 34 - 5 
24 148 13 36 - - - 12 7 - 5 
25 90 23 14 27 - 5 9 4 - - 
26 161 4 - - 1 - - - - 19 
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Date Lagos Kano FCT Katsina Bauchi Borno Ogun Oyo Jigawa Kaduna 
27 256 13 - 23 - 1 1 2 - 7 
28 111 3 16 - 1 1 4 8 - 6 
29 254 3 29 - 2 6 - 15 24 11 
30 378 9 52 6 - 7 13 5 5 12 
31 188 3 44 - 2 - 19 12 - 14 
 
Figure 8 – May 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in 10 most severely affected 
states in Nigeria 
 
 
Figure 9 – May 2020 epidemiological statistics of COVID-19/SARS-CoV-2 cases in 10 most severely affected 
states in Nigeria without Lagos 
 
No doubts that the COVID-19/SARS-CoV-2 was 
first recorded in the Ogun State of Nigeria, but 
Lagos state has surpassed both the daily infec-
tions and the cumulative infections for the coun-
try. On May 30, 2020, Lagos state recorded a 
daily total of 378 confirmed cases as shown in 
Table 4 and Fig. 8. Kano state had continued to 
follow in the rate at which cases are confirmed in 
Nigeria and followed by the other 8 states as 
shown in Table 5. 
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Analysis of Variance Result (ANOVA). The data 
sets were statistically analyzed using ANOVA; the 
experimental duration, daily infections and per-
centage discharge are the predictor variables 
while the total discharged, total deaths and total 
confirmed cases are the target variables of the 
regression in the ANOVA, model-independent 
variables were assessed to the three response or 
outcome variables as shown in Tables 6–8.  
 
Table 6 – Analysis of Variance for Total Discharged Response 
Source DF Adj SS Adj MS F-Value P-Value 
Regression 3 45505763 15168588 77.78 0.000 
Duration 1 875631 875631 4.49 0.037 
Daily infections 1 3474712 3474712 17.82 0.000 
% discharge 1 55333 55333 0.28 0.596 
Error 88 17162226 195025   
Total 91 62667989    
 
Table 7 – Analysis of Variance for Total Deaths Response 
Source DF Adj SS Adj MS F-Value P-Value 
Regression 3 588680 196227 149.60 0.000 
Duration 1 23005 23005 17.54 0.000 
Daily infections 1 34200 34200 26.07 0.000 
% discharge 1 997 997 0.76 0.386 
Error 88 115430 1312   
Total 91 704110    
 
Table 8 – Analysis of Variance for Total Confirmed Cases Response 
Source DF Adj SS Adj MS F-Value P-Value 
Regression 3 659902403 219967468 137.12 0.000 
Duration 1 20641294 20641294 12.87 0.001 
Daily infections 1 44711208 44711208 27.87 0.000 
% discharge 1 467384 467384 0.29 0.591 
Error 88 141168026 1604182   
Total 91 801070429    
 
The indices used for the statistical analysis are 
adjusted sum of square adjusted mean squares 
and P-value. The adjusted mean square helps to 
evaluate the variation of a model or system that 
predicts its response. It considers the degree of 
freedom and provides a platform for the compu-
tation of the adjusted coefficient of determination 
statistics (R2-adj) presented in the model sum-
mary. The adjusted sum of squares helps to as-
sess the various measures of different model pa-
rameters without taking into account the order 
of the independent variables of the model. It is 
also utilized for the computation of the p-value of 
the factor levels and also the coefficient of the 
determination statistics (R2); this is used to-
gether with the computed p-value for interpreta-
tion of model performance. 
The P-value provides the criteria for a rating of 
statistical significance within a hypothesis testing 
which shows where enough evidence exists for 
the acceptance or rejection of the conjecture or 
null hypothesis. For results interpretation, if P-
value >  then we accept the null hypothesis 
which means that the corresponding factor is not 
an important predictor and possesses negligible 
value within the model but if P-value > then we 
accept the alternate hypothesis which means that 
they are statistically significant to the prediction 
of the response parameter. 
From the computed results, % discharge factor 
has a p-value of 0.596, 0.386 and 0.591 for the 
three target responses respectively which indi-
cated that the % discharge factor is not signifi-
cant while the other factors; % confirmed and % 
deaths, in the predictor variables are statistically 
significant. 
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The Model Summary and Regression Coefficients. 
The developed regression model performance 
rating parameters are presented in the model 
summary for the derivation of the coefficient of 
determination (R2) which is the variation (in per-
centage) in the outcome explained by the MLR 
model. It is used to determine how well the 
model fits the system database; the higher the 
values, the better the model performance and its 
results range from a minimum of 0% to maxi-
mum of 100 % signifying that the fitted values 
are equal to the observed value. 
Regression Equation. The regression equation 
helps to express the relationship between the 
dependent variable or model response and inde-
pendent variables; it is expressed in the algebraic 
form of a regression line which takes the form of: 
 
nn xxy   ...110    (3) 
where y is the dependent or target variables, 0 is 
the constant term, n ,..., 21 is the regression 
coefficients and nxxx ,..., 21 is the independent or 
predictor variables.  
 
The model parameters are presented in Table 9. 
 
Table 9 – MLR Model Parameters 
Model Summary Coefficients of Regression 
Response Parameters S R2 (%) R2-Pred (%) R2-adj (%) Constant Duration Daily infections % discharge 
Total discharged 441.617 72.61 69.55 71.68 -369 10.42 3.287 3.88 
Total deaths 36.2174 83.61 81.81 83.05 -40.19 1.688 0.3261 -0.521 
Total confirmed cases 1266.56 82.38 80.44 81.78 -1284 50.6 11.79 -11.3 
 
The regression equations are presented in For-
mulas 4– 6 for the three target parameters as fol-
lows: 
 
TDs = -369 + 10.42 D + 3.287 DI + 3.88 PD  (4) 
TDt = -40.19 + 1.688 D + 0.3261 DI- 0.521 PD (5) 
TCC = -1284 + 50.6 D + 11.79 DI- 11.3 PD  (6) 
 
Where TDs is total discharge, TDt is total deaths, 
TCC is total confirmed cases, D is duration period, 
DI is daily infections, and PD is percentage dis-
charge 
Residual Plot. The residual plots show the resid-
ual values on the y-axis against the independent 
variable on the x-axis. The model residual results 
are obtained from the formula 7: 
 
predictedobservedresidual    (7) 
 
Since linear regression models are not always 
appropriate in terms of prediction performance, 
the evaluation of the appropriateness of the 
model is achieved by defining and examining the 
residual plots shown in Figures 10–12. 
The plots present the behavioural curves and 
Histogram charts of residuals which determine 
the skewness of the data under statistical exami-
nation; the normal probability plot of residuals 
which helps to verify the assumptions that re-
siduals are normally distributed, the residual vs 
fit plot helps to verify that the residuals possess 
constant variance and residual versus the order 
of data which helps to verify that the residuals 
are uncorrelated with each other. 
 
CONCLUSIONS 
From the foregoing epidemiological analysis and 
time prediction models of coronavirus (COVID-
19/SARS-CoV-2) spread in selected epicentres 
around the world with a focus on Nigeria case, it 
can be concluded with the following remarks. 
1. That the data of total confirmed cases, daily 
infections, daily discharge case, daily deaths, per-
centage discharge and deaths were successfully 
collected for three months through releases from 
the Nigeria Centre for Disease Control (NCDC). 
2. That the collected data were analysed and re-
sults presented in graphs to show the behaviour 
of the virus spread within the period under in-
vestigation. 
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Figure 11 – Residual Plots for Total deaths 
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Figure 12 – Residual Plots for Total confirmed cases 
 
CONCLUSIONS (CONTINUOUS) 
3. That a time prediction model was conducted 
using the MLR and ANOVA algorithms to predict 
what would be the behaviour of the virus spread 
in Nigeria in any period and the regression equa-
tions were proposed. 
That the proposed equations were validated as to 
established the functions that are more relevant 
to affect the results of the future predictions and 
this showed that total confirmed cases and total 
deaths are the independent variables that 
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